SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 3)*
Sangamo Biosciences, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
800677106
(CUSIP Number)
December 31, 2002
------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SCHEDULE 13G
CUSIP NO. 800677106
1. NAME OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NO'S. OF ABOVE PERSONS (ENTITIES ONLY).
Stephens Group, Inc.
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
3. SEC USE ONLY ________________________________________________
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Arkansas, USA
Number of Shares Beneficially Owned by Each Reporting Person With:
5. SOLE VOTING POWER 1,587,783
6. SHARED VOTING POWER 28,290
7. SOLE DISPOSITIVE POWER 1,587,783
8. SHARED DISPOSITIVE POWER 28,290
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY
EACH REPORTING PERSON 1,616,073
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES [ ]
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN
ROW (9) 6.6%
12. TYPE OF REPORTING PERSON HC
SCHEDULE 13G
CUSIP NO. 800677106
1. NAME OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NO'S. OF ABOVE PERSONS (ENTITIES ONLY).
Stephens-Sangamo Biosciences, LLC
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
3. SEC USE ONLY ________________________________________________
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Arkansas, USA
Number of Shares Beneficially Owned by Each Reporting Person With:
5. SOLE VOTING POWER 1,587,783
6. SHARED VOTING POWER -0-
7. SOLE DISPOSITIVE POWER 1,587,783
8. SHARED DISPOSITIVE POWER -0-
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY
EACH REPORTING PERSON 1,587,783
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES [ ]
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN
ROW (9) 6.5%
12. TYPE OF REPORTING PERSON OO
CUSIP NO. 800677106
ITEM 1.
(a) Name of Issuer: Sangamo Biosciences, Inc.
(b) Address of Issuer's Principal Executive Offices:
501 Canal Boulevard, Suite A100
Richmond, CA 94804
ITEM 2.
(a) Name of Person Filing: Stephens Group, Inc.
Stephens-Sangamo Biosciences, LLC
(b) Address of Principal Business Office or, if none, Residence
111 Center Street
Little Rock, Arkansas 72201
(c) Citizenship: Arkansas, USA
(d) Title of Class of Securities: Common Stock
(e) CUSIP Number: 800677106
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTIONS 240.13D-1(b),
OR 240.13D-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS
A: NA
ITEM 4. OWNERSHIP. PROVIDE THE FOLLOWING INFORMATION REGARDING THE
AGGREGATE NUMBER AND PERCENTAGE OF THE CLASS OF SECURITIES OF
THE ISSUER IDENTIFIED IN ITEM 1.
(a) Amount beneficially owned: 1,616,073
(b) Percent of class: 6.6%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote: 1,587,783
(ii) Shared power to vote or to direct the vote: 28,290
(iii) Sole power to dispose or to direct the disposition of: 1,587,783
(iv) Shared power to dispose or to direct the disposition of: 28,290
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities, check the following [ ].
N/A
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER
PERSON.
Stephens-Sangamo Biosciences, LLC is an investment LLC of which
Stephens Group, Inc. is the manager. Stephens Group, Inc. and the following
individuals and entities are members of the LLC:
Warren A. Stephens Trust UID 9/30/87
Harriet Calhoun Stephens Trust UID 3/22/84
Warren A. Stephens Grantor Trust UID 9/30/87
Grandchild's Trust #2
Bess C. Stephens Family Trust UID 1/4/85
W. R. Stephens, Jr. Revocable Trust UID 2/19/93
W. R. Stephens, Jr. Children's Trust UID 3/1/95
MAM Holdings, International, Inc.
Pamela Diane Stephens Trust One UID 4/10/92
Stephens Investment Partners III LLC
Jacoby Enterprises, Inc.
J and J Partners
Curtis F. Bradbury
Douglas H. Martin
Douglas H. Martin IRA
Martin Family Partnership III
C. Ray Gash IRA
Robert L. Schulte
K. Rick Turner
K. Rick Turner IRA
Robert Janes
Jackson Farrow Jr. IRA
William S. Walker
Gordon & Amanda Grender, jtwros
Andrew Stafford-Deitsch
Steve Goldman
Frank Lorge
Berry Summerour
Jason Zhang
The number of shares reported as being owned by Stephens Group, Inc.
also includes the ownership by Stephens Inc., its second-tier subsidiary, of 200
shares of the common stock of Sangamo Biosciences, Inc. ("SGMO") for its own
account and 28,090 shares held in discretionary
accounts for clients. In addition to the shares reported in Item 4, principals
of Stephens Group, Inc. own 235,212 shares of SGMO common stock. Stephens Group,
Inc. has no voting power or dispositive power over such shares and disclaims
beneficial ownership of these shares.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY. N/A
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP N/A
ITEM 9. NOTICE OF DISSOLUTION OF GROUP N/A
ITEM 10. CERTIFICATION.
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control of
the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose or
effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
February 14, 2003
-----------------
Date
Stephens Group, Inc.
and
Stephens-Sangamo Biosciences, LLC
By: /s/ David A. Knight
----------------------
David A. Knight
Vice President of Stephens Group, Inc.